1211327-92-2
1211327-92-2 structure
- Name: Peginterferon beta-1a
- Chemical Name: Peginterferon beta-1a
- CAS Number: 1211327-92-2
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2023-05-18 13:05:24
- Modify Date: 2024-04-05 18:32:03
-
Peginterferon beta-1a (Peginterferon β-1a) is the first pegylated interferon beta-1a molecule. Peginterferon beta-1a induces cancer cells Apoptosis and shows anti-tumor activities in nude mice models. Peginterferon beta-1a can be used for the research of cancer and multiple sclerosis (RMS)[1].
| Name | Peginterferon beta-1a |
|---|
| Description | Peginterferon beta-1a (Peginterferon β-1a) is the first pegylated interferon beta-1a molecule. Peginterferon beta-1a induces cancer cells Apoptosis and shows anti-tumor activities in nude mice models. Peginterferon beta-1a can be used for the research of cancer and multiple sclerosis (RMS)[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Peginterferon beta-1a (0.001-1000 ng/mL; 5 d) affects cell viability of SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cells[1]. Peginterferon beta-1a (10, 100, and 1,000 ng/mL) induces cell apoptosis[1]. Cell Viability Assay[1] Cell Line: SK-MEL-1, SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cell lines Concentration: 0.001-1000 ng/mL Incubation Time: 5 d Result: Inhibited the cell viability of SK-MEL-2, SK-MEL-5, MeWo and WM-266-4 tumor cells and showed an IC50 value of 2-3 ng/mL to WM-266-4 cells. Western Blot Analysis[1] Cell Line: WM-266-4 cell line Concentration: 10, 100 and 1000 ng/mL Incubation Time: 24 h Result: Induced the cleavage of PARP, caspase-8, and -9, induction of TRAIL and phosphorylation of STAT1. |
| In Vivo | Peginterferon beta-1a (0.1-1.6 mg/kg; s.c. QW/BIW/TIW for 3-4 weeks) inhibits SK-MEL-1, A-375 melanoma and WM-266-4 melanoma cancer growth in xenografts nude mice[1]. Animal Model: Nude mice with human SK-MEL-1 and A-375 melanoma xenografts[1] Dosage: 0.1-1.6 mg/kg Administration: Subcutaneous injection; once/twice a week; for 3/4 weeks Result: Significantly inhibited SK-MEL-1 tumor growth at 0.4 mg/kg (QW; 3 w) and inhibited A-375 melanoma tumors at 1.6 mg/kg (BIW; 4 w). Animal Model: Nude mice with human WM-266-4 melanoma xenografts[1] Dosage: 0.4-1.6 mg/kg Administration: Subcutaneous injection; 0.4-1.6 mg/kg; once/twice/three times a week for 4 w Result: The QW dose of 1.6 mg/kg and all doses given BIW and TIW induced tumor regression, with a 1.6 mg/kg QW dose induced significant tumor inhibition relative to 0.8 mg/kg QW. |
| References |
| No Any Chemical & Physical Properties |